Plain-English translation of NCT06676449 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether PD-1 inhibitors — a type of that helps your immune system fight cancer — works better when combined with radiation therapy and chemotherapy for advanced esophageal cancer. Some participants will receive the along with radiation and chemotherapy, while others will receive radiation and chemotherapy alone. The study wants to find out if adding this medication improves outcomes for patients with this type of cancer.
Esophageal squamous cell cancer is a serious disease, and current treatments don't work for everyone. Researchers believe that this medication might help by training your immune system to recognize and attack cancer cells more effectively, potentially improving survival and quality of life.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive radiation therapy (28 daily sessions over several weeks), chemotherapy (four cycles given every three weeks), and either the new medication or observation only. If assigned to receive the medication, you'll get intravenous infusions every three weeks for one year. Throughout the trial, you'll have regular visits with your care team for blood tests, scans, and check-ins to monitor how you're responding to treatment and manage any side effects. The full treatment and follow-up period lasts about one year.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China